Kailera Therapeutics Files for $533M IPO, Largest Obesity Biotech Debut Since Metsera

Clinical-stage Kailera aims to raise up to $533M on Nasdaq (ticker: KLRA), backed by four GLP-1-based candidates including a once-weekly injectable in Phase 3. The first obesity biotech IPO since Pfizer acquired Metsera for $10B signals renewed investor appetite for the $150B weight-loss market.